Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Earnings for Exscientia plc (EXAI)
Earnings in 2023 (TTM): $-162,088,000
According to Exscientia plc's latest financial reports the company's current earnings (TTM) are $-162,088,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Exscientia plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-162,088,000 | $-145,963,000 |
| 2022 | $-138,338,591 | $-116,735,924 |
| 2021 | $-41,687,394 | $-36,524,529 |
| 2020 | $-33,224,307 | $-30,367,826 |
| 2019 | $-10,547,018 | $-8,282,635 |